Company Overview and News

 
Recce Pharmaceuticals a leading ASX gainer after receiving additional R&D tax incentive rebate

2018-04-23 proactiveinvestors.com.au
Recce Pharmaceuticals Ltd (ASX:RCE) is a leading ASX gainer after receiving a further $861,590 R&D Tax Incentive Rebate from the Australian Government for its overseas Advanced Drug Development expenditure.

 
Recce Pharmaceuticals to discuss synthetic antibiotics at Proactive's CEO Sessions

2018-01-25 proactiveinvestors.com.au
Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed to address the urgent global health problem of antibiotic resistant superbugs.

 
Reward Minerals brings Tier 1 sulphate of potash project to Proactive's CEO Sessions

2018-01-18 proactiveinvestors.com.au
Reward Minerals Ltd (ASX:RWD) remains focused on the Tier 1 LD Sulphate of Potash Project in Western Australia.

 
Recce to reveal submission details from FDA

2017-11-15 proactiveinvestors.com.au
Recce Ltd (ASX:RCE) has been granted a trading halt by the ASX pending the receipt of information from the United States Food and Drug Administration (FDA) following Recce’s recent data submission.

 
Recce begins automated production of synthetic antibiotic

2017-07-20 proactiveinvestors.com.au
Recce (ASX:RCE) has started producing its antibiotic compounds at volumes at its new automated manufacturing facility in Sydney in preparation for human clinical trials.

 
Recce secures funding to fight antibiotic-resistant superbugs

2017-06-16 proactiveinvestors.com.au
Recce (ASX:RCE) has secured a flexible funding commitment of up to A$6.05 million from The Australian Special Opportunity Fund LP (ASOF).

 
Recce moves closer to clinical study application in the U.S.

2017-05-21 proactiveinvestors.com.au
Recce (ASX:RCE) has successfully verified the chemical structure and stability of its lead compound as it moves closer to completing the documentation required for its U.S. FDA application.

 
Recce continues to make progress against antibiotic-resistant superbugs

2017-03-27 proactiveinvestors.com.au
Recce’s (ASX:RCE) lead compound RECCE® 327 was found to be well tolerated with no adverse events in an independent study in large animals.

 
Recce Ltd reveals favourable safety data for antibiotic drug

2016-08-15 proactiveinvestors.com.au
Recce Ltd (ASX:RCE) has completed two tests demonstrating a sufficiently wide window between efficacy and toxicity of its lead drug candidate RECCE 327. RECCE 327 is an antibiotic and anti-cancer drug that fights against viruses and bacteria, including superbugs, even after repeated use. The first test was conducted upon 6 groups of 10 mice each. The test indicated a large therapeutic window of between the 70 mg/kg and 280 mg/kg of RECCE 327 per mouse.

 
Recce Ltd has early stage test success against influenza virus

2016-07-13 proactiveinvestors.com.au
Recce Ltd (ASX:RCE) has achieved anti-viral activity against influenza virus during in-vitro testing of its lead drug RECCE 327. Recce specialises in the development of antibiotics and anti-cancer drugs that fights against bacteria, including superbugs, even after repeated use. The test data suggests that RECCE 327 may be used to target Influenza A virus (H1N1) located external to cells and thus preventing the virus from spreading.

 
Shares to be Released from Escrow

2016-05-10 asx.com.au

 
Recce - The Way Forward

2016-05-03 asx.com.au

 
Appendix 4C - quarterly

2016-04-27 asx.com.au

 
Progress Update

2016-04-11 asx.com.au

 
Final Directors Interest Notice

2016-04-11 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...